NCT06449859View on ClinicalTrials.gov

A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Asthma
Interventions
DRUG

TQC2938 Injection

TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

DRUG

TQC2938 Placebo

TQC2938 Placebo is a placebo comparator

Trial Locations (1)

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY